Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
171.88
+0.09 (+0.05%)
4:54:26 PM EDT: $171.80 -0.08 (-0.05%)
Regulatory, Other Pre-Announcement

Johnson & Johnson Reports Q2 2021 Results

Published: 07/21/2021 10:41 GMT
Johnson & Johnson (JNJ) - Reports Q2 2021 Results.
Q2 Sales $23.3 Billion Versus Refinitiv Ibes Estimate of $22.21 Billion.
J&j - Company Increasing 2021 Full-year Guidance for Sales and Eps.
J&j - EPS of $2.35 Increased 72.8% in Q2 2021.
J&j - Qtrly Adjusted EPS of $2.48 Increased 48.5%.
J&j - Qtrly Worldwide Covid-19 Vaccine Sales $164 Million.
J&j Sees 2021 Adjusted Operational Sales Change Versus.
Prior Year 12.5% - 13.5%.
J&j -sees FY 2021 Adjusted Operational EPS (diluted) $9.50 - $9.60.
J&j - Qtrly Worldwide Darzalex Sales $1.43 Billion Versus $901 Million Reported Last Year.
Q2 Earnings per Share View $2.27 -- Refinitiv Ibes Data (analyst estimates).
J&j -sees FY 2021 Adjusted EPS (diluted) $9.60 - $9.70.
J&j Sees 2021 Operational Sales $92.5 Billion - $93.3 Billion.
J&j - Qtrly Worldwide Imbruvica Sales $1.12 Billion Versus $949 Million Reported Last Year.
J&j Sees 2021 Estimated Reported Sales $93.8 Billion - $94.6 Billion.
FY2021 Earnings per Share View $9.52, Revenue View $91.24 Billion -- Refinitiv Ibes Data (analyst estimates).
J&j - Qtrly Results Included Litigation Related Positive Pre-tax Adjustments of $23 Million.